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Abstract 
Background: Mycoplasma pneumoniae is a common pathogen that causes community‑acquired pneumonia in 
school‑age children. Macrolides are considered a first‑line treatment for M. pneumoniae infection in children, but mac‑
rolide‑refractory M. pneumoniae (MRMP) strains have become more common. In this study, we assessed the efficacy 
of tetracyclines and fluoroquinolones in MRMP treatment in children through a systematic review and meta‑analysis.
Methods: Two reviewers individually searched 10 electronic databases (Medline/Pubmed, Embase, the Cochrane 
Library, and core Korean, Chinese, and Japanese journals) for papers published from January 1, 1990 to March 8, 2018. 
The following data for each treatment group were extracted from the selected studies: intervention (tetracyclines 
and fluoroquinolones/comparator), patient characteristics (age and sex), and outcomes (fever duration, hospital stay 
length, treatment success rate, and defervescence rates 24, 48, and 72 h after starting treatment).
Results: Eight studies involving 537 participants were included. Fever duration and hospital stay length were shorter 
in the tetracycline group than in the macrolide group (weighted mean difference [WMD] = − 1.45, 95% confidence 
interval [CI]: − 2.55 to − 0.36, P = 0.009; and WMD = − 3.33, 95% CI: − 4.32 to − 2.35, P < 0.00001, respectively). The 
therapeutic efficacy was significantly higher in the tetracycline group than in the macrolide group (odds ratio [OR]: 
8.80, 95% CI: 3.12–24.82). With regard to defervescence rate, patients in the tetracycline group showed significant 
improvement compared to those in the macrolide group (defervescence rate after 24 h, OR: 5.34, 95% CI: 1.81–15.75; 
after 48 h, OR 18.37, 95% CI: 8.87–38.03; and after 72 h, OR: 40.77, 95% CI: 6.15–270.12). There were no differences in 
fever improvement within 24 h in patients in the fluoroquinolone group compared to those in the macrolide group 
(OR: 1.11, 95% CI: 0.25–5.00), although the defervescence rate was higher after 48 h in the fluoroquinolone group (OR: 
2.78, 95% CI: 1.41–5.51).
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Background
Mycoplasma pneumoniae (MP) is a common causative 
pathogen of community-acquired pneumonia (CAP) 
worldwide, particularly in school-age children and ado-
lescents [1, 2]. The prevalence of pediatric CAP ranges 
from 10 to 40% [3]. Although MP infection often causes 
self-limiting disease, it may also develop into severe 
pneumonia with extra-pulmonary complications [4, 5].
β-Lactam antibiotics, which are active against most res-
piratory bacterial pathogens, are ineffective against MP 
due to the lack of cell wall. Protein synthesis inhibitors, 
such as macrolides and tetracyclines, or DNA synthesis 
inhibitors, such as fluoroquinolones, are usually effec-
tive against MP in vitro, and are the drugs of choice for 
MP infections. In children, macrolides are the only rec-
ommended first-line treatment for MP infection due to 
age-related safety issues with the use of tetracyclines and 
fluoroquinolones [6]. However, in recent years, the preva-
lence of macrolide-refractory MP (MRMP) infection has 
rapidly increased among children, particularly in East 
Asian countries such as Korea, Japan, and China [7–9].
The clinical implications of MRMP have not been 
fully elucidated with regard to whether resistant strains 
can cause more serious or long-term disease, and mac-
rolides may be clinically effective even in the presence 
of resistance [10, 11]. However, several studies have 
revealed that MRMP is associated with a longer febrile 
and hospital stay period, prolonged antibiotic use, 
and a high frequency of pneumonia aggravation and 
extrapulmonary complications [10]. Therefore, alterna-
tive antibiotic treatment options are needed in severe 
MRMP cases with clinical deterioration.
Alternative antibiotic treatment options for MRMP 
infections include tetracyclines and fluoroquinolones. 
However, the use of these agents in children is lim-
ited because of their toxicity. Tetracyclines may cause 
adverse effects such as hypoplasia of the enamel, per-
manent gray/brown staining of the teeth, and transient 
anostosis in children [12]. Therefore, they are contrain-
dicated for patients younger than 8  years. Fluoroqui-
nolones are not usually prescribed as a first-line therapy 
for CAP in children as they have been reported to 
cause cartilage erosion in young animals [13]. Despite 
this concern, fluoroquinolones have been safely used 
to treat severe infections in children in the absence of 
other safe and effective alternatives [14].
Recently, studies have reported the use of second-line 
antimicrobial agents such as tetracyclines and fluoro-
quinolones for treating MRMP infection in children. In 
this study, we evaluated the efficacy of tetracyclines and 
fluoroquinolones against MRMP infection in children 
through a systematic review and meta-analysis.
Methods
Search strategy
To identify relevant studies, we performed an extensive 
search across 10 electronic full-text databases [Med-
line/Pubmed, Embase, the Cochrane Library, KoreaMed 
(https:// korea med. org), National Digital Science Library 
(http:// www. ndsl. kr), Korean medical database (http:// 
kmbase. medric. or. kr), Research Information Sharing 
Service (http:// www. riss. kr), Koreanstudies Information 
Service System (http:// kiss. kstudy. com), China National 
Knowledge Infrastructure (http:// www. cnki. net), and 
Japan Medical Abstracts Society, Igaku Chuo Zasshi 
(http:// www. jamas. or. jp)] with no language restrictions. 
Two independent medical librarians (D.W.S. and M.L.) 
searched articles published from January 1, 1990 to 
March 8, 2018 using a protocol designed for this study. 
The search terms used for each database are listed in 
Additional file 1. Databases from Korea, China, and Japan 
were chosen as the data from these have shown a high 
prevalence of MP and MRMP.
Eligibility
Articles that met the following inclusion criteria were 
included: (1) the study topic was MRMP, defined as dis-
ease showing no clinical or radiological improvement 
48–72 h after macrolide administration; (2) the subjects 
were children aged ≤ 18 years; (3) the study was designed 
as a randomized controlled trial (RCT) or an observa-
tional study with controls; (4) the intervention agent was 
a non-macrolide antibiotic known to be active against 
MP, such as tetracyclines and fluoroquinolones; (5) the 
control was a macrolide drug; and (6) at least one of the 
predetermined outcomes was reported.
Animal and preclinical studies, as well as articles other 
than original research articles (e.g., reviews, editori-
als, letters, conference abstracts, and comments) were 
excluded. Studies with duplicate subjects (i.e., different 
studies using the same outcome indicators in the same 
number of patients) were also excluded. Our search 
Conclusion: Tetracyclines may shorten fever duration and hospital stay length in patients with MRMP infection. Fluo‑
roquinolones may achieve defervescence within 48 h in patients with MRMP infection. However, these results should 
be carefully interpreted as only a small number of studies were included, and they were heterogeneous.
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strategy implemented no language restrictions, and 
non-English articles were translated and included for 
evaluation.
Study selection, quality assessment, and data extraction
Studies were initially screened by two independent 
reviewers (J.G.A. and H.K.C.) based on the title and 
abstract, followed by full-text screening. The literature 
selection process was conducted in accordance with the 
Preferred Reporting Items for Systematic Reviews and 
Meta-Analysis Protocols 2015 statement (Fig.  1) [15]. 
The quality of the selected studies was assessed using 
the Cochrane Risk of Bias Tools [16] for RCTs and the 
revised Risk of Bias Tool for Non-Randomized Studies 
[17] for observational studies. The data extraction form 
included the following information: first author, year of 
publication, population in each group, antibiotic treat-
ment (tetracycline or fluoroquinolone/comparator), 
patient characteristics (age and sex), and outcomes (dura-
tions of fever and hospitalization, therapeutic efficacy, 
and defervescence rates at 24, 48, and 72 h after starting 
treatment). Therapeutic efficacy was defined as the rate of 
achieving clinical recovery with no fever, improvement or 
disappearance of cough, and improved or normal labora-
tory values. Study selection, quality assessment, and data 
extraction were conducted by two independent reviewers 
(J.G.A. and H.K.C.). Any disagreements were resolved 
through discussion with a third reviewer (K.H.K.). If the 
results of the selected studies were unclear or missing, 
we contacted the corresponding study investigators to 
obtain or confirm data.
Statistical analysis
We pooled the findings from the included studies and 
calculated mean, standard deviation, and sample size. 
For outcomes presented as continuous variables, such 
as fever duration, hospital stay length, and therapeutic 
efficacy, we calculated mean differences with 95% confi-
dence intervals (CIs). For dichotomous outcomes such as 
the achievement of defervescence after 24, 48, and 72 h 
of treatment, we calculated odds ratios (ORs) with 95% 
CIs. The average effect summary was calculated using a 
random-effects model (Mantel–Haenszel method) using 
Review Manager 5.3 (The Cochrane Collaboration, Lon-
don, UK) including the I2 statistic. I2 of 25%, 50%, and 
75% indicated low, moderate, and high heterogeneity, 
respectively [18]. To assess the risk of publication bias, 
we used funnel plots for visual inspection; Egger test 
Fig. 1 Flowchart of the selection process of studies included in the meta‑analysis
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and the trim-and-fill method were used for statistical 
identification.
Results
Eight studies involving 537 participants were reviewed 
in this study. The characteristics of the studies included 
in this meta-analysis are presented in Table  1 and bias 
assessment results are shown in Figs. 2, 3, 4, 5, 6, 7. Pub-
lication bias was not assessed, because only a few trials 
were included and therefore, appropriate assessment 
with funnel plots or advanced regression-based methods 
could not be performed.
Macrolides vs. tetracyclines
Fever duration
In the three RCTs included [19–21], fever duration was 
shorter in the tetracycline group than in the macrolide 
group (weighted mean difference [WMD] =  −  1.45, 
95% CI: −  2.55 to −  0.36, P = 0.009). However, consid-
ering the significant inter-study heterogeneity (I2 > 50%), 
we conducted subgroup analysis to compare the effects 
of combination treatment with tetracycline and mac-
rolide with that of tetracycline-only treatment. Subgroup 
analysis revealed the superior effects of tetracycline 
compared with macrolide. The high heterogeneity of the 
combination subgroup (tetracycline and macrolide treat-
ment) can be attributed to the high effect observed in 
Li’s study. Therefore, these outcomes were assessed using 
a random-effects model considering inter- and intra-
study variation, which confirmed that fever duration 
was significantly shorter in the tetracycline group than 
in the macrolide group (combination treatment vs. mac-
rolide-only treatment, WMD = − 1.92, 95% CI: − 2.63 to 
− 1.21, P < 0.00001; tetracycline-only treatment vs. mac-
rolide-only treatment, WMD = − 0.60, 95% CI: − 0.97 to 
− 0.23, P = 0.001, Fig. 2).
Hospital stay length
In two RCTs [19, 21], the length of hospital stay was 
shorter in the tetracycline group than in the mac-
rolide group (WMD = − 3.33, 95% CI: − 4.32 to − 2.35, 
P < 0.00001, Fig.  3). There was no significant inter-study 
heterogeneity in terms of outcome (I2 < 50%).
Therapeutic efficacy
Two RCTs [20, 21] were assessed to compare treatment 
efficacy in the tetracycline and macrolide groups. Thera-
peutic efficacy was significantly higher in the tetracycline 
group than in the macrolide group (OR: 8.80, 95% CI: 
3.12–24.82, Fig.  4). There was no significant inter-study 
heterogeneity in terms of outcome (I2 < 50%).
Defervescence after 24, 48, and 72 h
In the two prospective observational studies included 
[22, 23], the defervescence rate 24  h after starting 
treatment was compared between tetracycline- and 
macrolide-treated groups. The 24-h defervescence rate 
was significantly higher in the tetracycline group than 
in the macrolide group (OR: 5.34, 95% CI: 1.81–15.75, 
Fig. 5a). There was no significant inter-study heteroge-
neity in this outcome (I2 < 50%).
In the five prospective observational studies assess-
ing the defervescence rate 48 h after starting treatment 
[22–26], the 48-h defervescence rate was higher in the 
tetracycline group than in the macrolide group (OR: 
18.37, 95% CI: 8.87–38.03, Fig.  5b). There was no sig-
nificant inter-study heterogeneity in terms of this out-
come (I2 < 50%).
Two prospective observational studies [22, 23] com-
pared the defervescence rate between the tetracycline 
and macrolide groups 72  h after starting treatment. 
The 72-h defervescence rate was higher in the tetra-
cycline group than in the macrolide group (OR: 40.77, 
95% CI: 6.15–270.12, Fig. 5c). There was no significant 




There was no significant difference between the tosu-
floxacin and macrolide groups with regard to 24-h 
defervescence rate in two prospective observational 
studies [22, 26] (OR: 1.11, 95% CI: 0.25–5.00, Fig.  6a). 
There was no significant inter-study heterogeneity with 
regard to this outcome (I2 < 50%).
Three prospective observational studies [22, 25, 26] 
compared the 48-h defervescence rate between the 
tosufloxacin and macrolide groups. The tosufloxacin 
group showed a higher defervescence rate than the 
macrolide group (OR: 2.78, 95% CI: 1.41–5.51, Fig. 6b). 
There was no significant inter-study heterogeneity with 
regard to this outcome (I2 < 50%).
Tetracyclines vs. tosufloxacin
Defervescence after 48 h
Two prospective observational studies [22, 25] com-
pared the defervescence rate 48  h after starting treat-
ment between the tosufloxacin and tetracycline groups. 
The tetracycline group showed a significantly higher 
48-h defervescence rate than the tosufloxacin group 
(OR: 0.32, 95% CI: 0.13–0.76, Fig. 7). There was no sig-
nificant inter-study heterogeneity in terms of this out-
come (I2 < 50%).
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Discussion
To the best of our knowledge, this is the first meta-anal-
ysis to assess the efficacy of tetracyclines and fluoroqui-
nolones against MRMP infection in children. Although 
the clinical relevance of macrolide-resistant strains has 
not been established, severe refractory cases caused by 
such strains have been reported, and there is a need for 
alternative treatments [11]. Several studies on antibiotic 
treatment of MRMP infections have been published in 
the past decade, but the number of subjects has been 
small; moreover, multinational studies have not been 
conducted. Therefore, in this meta-analysis, data from 
multiple countries were combined to compare the effect 
of secondary antibiotics with that of macrolide treat-
ment in MRMP treatment. In this systematic review 
and meta-analysis, we evaluated three RCTs and five 
prospective observational studies comparing treatment 
responses between the macrolide and second-line anti-
biotic treatment groups in children with MRMP infec-
tion. Our review revealed that tetracyclines can shorten 
fever duration and length of hospital stay, as well as 
achieving defervescence at 24, 48, and 72  h after start-
ing treatment; with fluoroquinolones, defervescence can 
be achieved within 48 h. Although some data suggested 
Fig. 2 Comparison of fever duration between patients treated with tetracyclines and those treated with macrolides
Fig. 3 Comparison of hospital stay length between patients treated with tetracyclines and those treated with macrolides
Fig. 4 Comparison of treatment efficacy between patients treated with tetracyclines and those treated with macrolides
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Fig. 5 Forest plots of defervescence rates in patients treated with tetracyclines or macrolides. The defervescence rates at 24 h (a), 48 h (b), and 72 h 
(c) are shown
Fig. 6 Forest plots of defervescence rates in patients treated with tosufloxacin or macrolides. The defervescence rates at 24 h (a) and 48 h (b) are 
shown
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that tetracyclines may be more effective than fluoroqui-
nolones in achieving defervescence after 48 h in patients 
with MRMP infection, there was not enough evidence to 
determine the superiority of one group over the other.
Tetracyclines are recommended only for use in chil-
dren aged ≥ 8  years based on reports of permanent 
tooth discoloration and tooth enamel hypoplasia in chil-
dren receiving first-generation tetracyclines [12]. Pre-
vious studies have reported that visible dental staining 
occurred in 23–92% of children treated with tetracyclines 
[27–31], and it correlated with the dose and duration of 
treatment [12, 27]. However, data showing an association 
between treatment with new-generation tetracyclines, 
such as doxycycline and minocycline, and dental stain-
ing are limited. A recent study reported that the short-
term use of doxycycline in children aged < 8 years for the 
treatment of Rocky Mountain spotted fever did not cause 
dental staining, enamel hypoplasia, or changes in tooth 
color [32]. In addition, updated recommendations from 
the American Academy of Pediatrics now include the 
use of doxycycline for ≤ 21  days in children of all ages, 
on the grounds that doxycycline binds less avidly to cal-
cium than other tetracyclines and that the risk of dental 
staining associated with short courses is minimal [33]. 
All tetracyclines in studies included in our meta-analysis 
were new-generation tetracyclines (minocycline, n = 6; 
doxycycline, n = 1). Most of the patients in the tetracy-
cline group were aged ≥ 8 years, and they benefited from 
this treatment. Considering that new-generation tetra-
cyclines are licensed for use in patients aged ≥ 8  years 
in many countries, they may be the preferred choice for 
treating MRMP infections in children aged ≥ 8 years.
The use of fluoroquinolones in children is usually 
reserved for specific indications because of their poten-
tial risk of musculoskeletal toxicity. Currently, they are 
approved by the U.S. Food and Drug Administration for 
use in children aged < 18 years only for the treatment of 
complicated urinary tract infections and pyelonephritis 
and the treatment and prevention of inhalation anthrax 
[14]. Concerns regarding musculoskeletal toxicity in 
children are based on a study in juvenile animals show-
ing the development of erosive arthropathy in weight-
bearing joints [34]. Safety data on fluoroquinolones in 
humans are limited, but some clinical trial data suggest 
that adverse musculoskeletal events in children are usu-
ally mild and reversible [14, 34–36]. Our meta-analysis 
results provide information about the clinical efficacy of 
fluoroquinolones in achieving defervescence within 48 h 
of administration in pediatric patients with MRMP infec-
tion. Therefore, fluoroquinolones may be an appropriate 
option for the treatment of MRMP infection in children.
In adults, there are concerns regarding fluoroquinolone 
resistance to respiratory pathogens other than MP [37]. 
In addition, fluoroquinolones have induced resistance in 
MP strains in vitro [38]. Accordingly, although the guide-
lines of the Infectious Diseases Society of America and 
the American Thoracic Society do not include detailed 
recommendations for alternative antibiotic treatment for 
MRMP, macrolides or tetracyclines are recommended as 
a first-line treatment for adults with MP infection, and 
fluoroquinolones as a second-line therapy [39]. Because 
there are concerns that indiscriminate use of quinolones 
may delay tuberculosis diagnosis in countries with a high 
prevalence of tuberculosis [40], such as China and Korea, 
the use of quinolones should be limited only to patients 
diagnosed with MRMP infections.
Our study had several limitations. First, all included 
studies had a small number of patients and relatively 
heterogeneous methodologies. There were differences 
among studies in terms of the type, dose, and treatment 
duration of tetracyclines and fluoroquinolones used, 
MRMP diagnosis, and study protocol. Second, the quality 
of the studies included in the analysis varied substantially, 
which may have affected the robustness of our outcomes. 
To overcome these limitations, we evaluated the included 
studies using credible tools (Cochrane Risk of Bias Tools 
for RCTs and the revised Risk of Bias Tool for Non-Ran-
domized Studies for observational studies) that could 
appropriately evaluate the risk of bias; the risk of bias 
assessment results is summarized in Figs.  2–7. In addi-
tion, a random-effects model was used to overcome the 
heterogeneity that can be caused by this bias, and sub-
group analysis was performed in cases of heterogeneity. 
Third, as the studies included in our analysis did not pro-
vide sufficient data on the safety of tetracyclines or fluo-
roquinolones, a meta-analysis of safety was not possible. 
Fig. 7 Forest plot of 48‑h defervescence rates in patients treated with tosufloxacin or tetracyclines
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None of the studies that described safety reported cases 
that were affected by adverse effects. Fourth, in this meta-
analysis, we only included tosufloxacin, which is an oral 
fluoroquinolone approved for administration to children 
with otitis media or pneumonia in Japan, in the fluoro-
quinolone group. However, there have been reports that 
other fluoroquinolones, such as levofloxacin, have also 
been used to treat MRMP infection in children [41, 42], 
but they were excluded because they did not meet the 
inclusion criteria of this study. Further comparative stud-
ies are needed to evaluate the efficacy of other fluoroqui-
nolones to treat MRMP infection in children. Finally, as 
there were limited studies on the use of fluoroquinolones 
in children with MRMP infection, we could not compare 
the length of hospital stay or therapeutic efficacy between 
fluoroquinolones and macrolides.
Conclusions
The results of this meta-analysis revealed the clinical 
efficacy of tetracyclines and fluoroquinolones against 
MRMP infection in children. Although based on limited 
evidence, our results suggest that tetracyclines and fluo-
roquinolones may be used as a second-line therapy in the 
treatment of pediatric MRMP infection.
These results should be carefully interpreted, however, 
as the number of studies included was small and the 
study methodologies used were heterogeneous. In addi-
tion, the safety of tetracyclines and fluoroquinolones in 
children has not yet been established, and the studies 
analyzed did not provide sufficient safety data. More pro-
spective clinical studies with a larger number of patients 
are required to validate the effectiveness and safety of tet-
racyclines and fluoroquinolones against MRMP infection 
in children.
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